Betulin isolated from Pyrola incarnata Fisch. inhibited lipopolysaccharide (LPS)-induced neuroinflammation with the guidance of computer-aided drug design.

This study aims to investigate active phytochemicals isolated from Pyrola incarnata Fisch. (P. incarnata) and their protection against neuroinflammation induced by LPS. Betulin, accompanied with other 9 compounds, were isolated from P. incarnata and elucidated by spectroscopic analysis (1H-, 13C NMR). ELISA kits and the measurement of NO production based on Griess reaction showed that betulin (5) (250 µg/mL) could suppress LPS-induced activation of microglial cell BV-2 better than others by inhibiting inflammatory cytokines (TNF-α, IL-6, IL-1ß) expression and NO production. With the guidance of computer-aided drug design and the analysis of biological experiment, we demonstrated betulin could reduce LPS-induced iNOS expression, prevent JNKs pathways, and down-regulate the phosphorylation levels of NF-κB/p65. In conclusion, betulin isolated from P. incarnata possessed outstanding anti-neuroinflammation potential, presumably related to iNOS expression, JNKs and NF-κB/p65 pathways. Therefore, Pyrola incarnata may be a valuable natural resource and betulin is a potential drug for the treatment of neurodegenerative disorders by inhibiting inflammatory mediators.

Crystal structure of N-{4-[(6-chloro-pyridin-3-yl)meth-oxy]phen-yl}-2,6-di-fluoro-benzamide.

In the title compound, C19H13ClF2N2O2, the conformation of the N-H bond in the amide segment is anti to the C=O bond. The mol-ecule is not planar, with dihedral angles between the central benzene ring and the outer benzene and pyridyl rings of 73.35 (7) and 81.26 (6)°, respectively. A weak intra-molecular C-H⋯O hydrogen bond occurs. In the crystal, N-H⋯N, C-H⋯O and C-H⋯F hydrogen bonds lead to the formation of dimers. The N-H⋯N inversion dimers are linked by π-π contacts between adjacent pyridine rings [centroid-centroid = 3.8541 (12) Å] and C-H⋯π inter-actions. These contacts combine to stack the mol-ecules along the a axis.

New cytotoxic alkylated anthraquinone analogues from a soil actinomycete Streptomyces sp. WS-13394.

Four new alkylated anthraquinone analogues (1-4) were isolated from a soil actimomycete Streptomyces sp. WS-13394. The structures of compounds 1-4 were elucidated to be 1,4,6-trihydroxy-8-alkylanthraquinones by means of spectroscopic methods, including UV, one dimensional (1D), 2D-NMR and MS spectrometry. All compounds showed activities against BGC-823 and MCF-7 with IC50 from 0.99 to 3.54 µg/mL, while 2 exhibited cytotoxicity against HepG2, A875, BGC-823 and MCF-7 with IC50 2.29, 4.90, 0.99, and 1.66 µg/mL, respectively.

Efficacy of arbidol on lethal hantaan virus infections in suckling mice and in vitro.

AIM: Arbidol is an immunomodulator that was first developed in Russia. In this study, we report the antiviral activity of arbidol against Hantaan virus (HTNV) in vitro and in vivo. METHODS: The antiviral activity of arbidol in vitro was determined by plaque-forming assay, ranging from 0.5 to 8 microg/mL. To investigate whether arbidol has an antiviral effect in vivo, suckling BALB/c mice infected with HTNV were treated with arbidol at 24 h before infection with a 5, 10 or 20 mg.kg(-1).d(-1), once per day, for 10 days. On day 12 and 28 post infection (pi), histopathological changes and viral antigen were detected. On days 4, 8, 12, and 16 pi, the viral load of target organs and serum TNF-alpha levels of arbidol-treated animals were determined. RESULTS: Arbidol was found to have potent inhibitory activity against HTNV when added in vitro before or after viral infection, with a 50% inhibitory concentration (IC(50)) of 0.9 and 1.2 microg/mL, respectively. The 50% lethal dose (LD(50)) of arbidol for suckling mice was 78.42 mg.kg(-1).d(-1). Oral administration of arbidol increased both survival rate and mean time to death (MTD). Treatment with arbidol reduced histopathological changes, decreased viral load and viral antigen levels, and modulated the level of serum TNF-alpha. CONCLUSION: Arbidol has the ability to elicit protective antiviral activity against HTNV in vivo and in vitro.Acta Pharmacologica Sinica (2009) 30: 1015-1024; doi: 10.1038/aps.2009.53; published online 8 June 2009.

[Antiviral effect of epigallocatechin gallate (EGCG) on influenza A virus].

OBJECTIVE: To investigate the effects of epigallocatechin gallate (EGCG) against the influenza A virus in vitro and in vivo. METHOD: The cell culture technique was used in MDCK cells to get cell viability at different concentration of EGCG by MTT assay. Cytopathic effect (CPE) and MTT were applied to observe the protective function of EGCG and it's ingredients were administered to cells in three different ways (method I: administration before infection, method II: administration upon infection, and method II: administration after infection) to treat the infectious model in vitro. The anti-viral activity in vivo was performed on BALB/c mice, which were divided to receive EGCG. The mean survival days and the pulmonary pathological lesions of the infected mice were observed to evaluate the therapeutic efficacy of EGCG. RESULT: EGCG effectively inhibited influenza A virus in vitro. The death rate and pulmonary pathological lesions were decreased, and the mean survival days were prolonged by oral administration of EGCG in the mice infected by influenza A virus. CONCLUSION: EGCG has a strong effect against influenza A H1 N1 virus in vitro and in vivo, in a dose-dependent manner.